SecBot SecBot
144 ·Filed Aug 5, 2026

MRNA

Moderna, Inc.
BEARISH
Impact 6/10
Horizondays Processed3mo ago SEC0001959173-26-005661
Actionable Insight ▼ Bearish

Monitor for the actual sale on Form 4 and any subsequent insider selling patterns. The CEO's intent to sell a large block after a stock option exercise could pressure the stock near-term. Watch for any accompanying negative news or guidance changes in upcoming filings.

DirectionBearish
Confidencemedium
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$56.26
T+0 close · Aug 5, 2026 · via day close
Latest settled
+295.98%
T+60 · $222.76
Vs SPY
+296.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $56.26entry
  2. T+1 · 3mo ago −4.26%α −4.10% · $53.86
  3. T+5 · 3mo ago +13.18%α +12.83% · $63.67
  4. T+20 · 3mo ago +168.08%α +168.68% · $150.81
  5. T+60 · 19d ago +295.98%α +296.04% · $222.76
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Stephane Bancel filed a Form 144 on August 5, 2026, indicating intent to sell 499,246 shares of Moderna common stock, valued at approximately $28.96 million. The shares were acquired via stock option exercise, and the sale is planned through Fidelity Brokerage Services. This is a material insider sale by the CEO, representing a notable portion of his holdings, and may signal a lack of near-term confidence or a planned diversification event.

Key Facts

  • CEO Stephane Bancel filed a Form 144 to sell 499,246 shares of Moderna common stock.
  • The proposed sale value is approximately $28,956,268 based on the filing date (August 5, 2026).
  • Shares were acquired via stock option exercise on the same date (August 5, 2026).
  • The sale is planned through Fidelity Brokerage Services LLC.
  • Bancel is listed as both an Officer and Director of Moderna.
  • The filing was made on August 5, 2026, and accepted the same day.

Financial Impact

CEO proposes to sell ~$28.96 million worth of shares, representing a significant insider monetization event.

insider holdingsdilution (from option exercise)

Risk Factors

  • CEO selling a large stake may signal lack of confidence or foreshadow weak fundamentals.
  • The sale could increase selling pressure and dampen investor sentiment.
  • Option exercise and immediate sale may be viewed as compensation monetization, but size is notable.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
30% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (MRNA), Batch item 10001959173-26-005661
Document: 0001959173-26-005661-index.html0001959173-26-005661
Document: 0001959173-26-005661.txt0001959173-26-005661
144 Filing (MRNA), Batch item 40001959173-26-005661
Document: 0001959173-26-005661-index.html0001959173-26-005661
Document: 0001959173-26-005661.txt0001959173-26-005661

Track record

26 reports on MRNA

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
  2. Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
  3. Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
  6. Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
  8. Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
  9. Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
  10. Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 6h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026